In 2021, ATYR completed a phase 1b/2a trial in pulmonary sarcoidosis, and have since started a phase 3 trial. Currently the ...

The presence of gastroesophageal reflux disease (GERD) is associated with an increased incidence of pulmonary diseases, but ...

With significant hedge fund interest and a share price under $10, Gossamer Bio, Inc. (NASDAQ:GOSS) secures a spot on our list ...

Advances in classification and treatment of idiopathic inflammatory myopathies highlight the role of biomarkers, ...

Liquidia Corporation (NASDAQ:LQDA) is one of the 11 Best Short Squeeze Stocks to Buy Now. Price targets raised by analysts ...

A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the ...

California is witnessing a sharp and unsettling rise in Valley Fever cases, officially known as coccidioidomycosis, and 2025 is unfolding as another record-breaking year. With the year not yet over, ...

In a significant research advancement that may help inform treatment strategies for millions of patients worldwide, a ...

The FDA granted breakthrough therapy designation to Ifinatamab deruxtecan for some with extensive-stage small cell lung ...

Humans are programmed to follow intellectual fashions. In the field of chronic obstructive pulmonary disease (COPD), the concept that inflammation is the core problem is dominant, whereas other key ...

BC, AOCNP, explained that adverse effects are common among the available antibody-drug conjugates in breast cancer.

Yutrepia, prescribed to over 900 PAH or PH-ILD patients since its May U.S. approval, increased walking distances by over 100 ...